Related Experiment Video

Updated: Feb 19, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

7.5K

Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their

Camilo Ayala-Breton1, Lukkana Suksanpaisan, Emily K Mader

  • 1Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|July 12, 2013
PubMed

Insights

A novel hybrid vesicular stomatitis/measles virus (VSV/MV) shows enhanced tumor-killing capabilities. This oncolytic virus combines the safety of measles virus with the rapid spread of VSV, outperforming existing therapies in preclinical models.

Area of Science:

  • Virology
  • Oncology
  • Gene Therapy

Background:

  • Oncolytic viruses offer diverse mechanisms for tumor destruction.
  • Measles virus (MV) is safe but slow, while vesicular stomatitis virus (VSV) is fast but neurotoxic.
  • Existing oncolytic viruses have limitations in safety, speed, or efficacy.

Purpose of the Study:

  • To develop a hybrid oncolytic virus combining the strengths of VSV and MV.
  • To create a virus with rapid replication, tumor cell lysis, and enhanced safety.
  • To evaluate the in vivo efficacy of the hybrid VSV/MV in a myeloma model.

Main Methods:

  • Construction of a hybrid vesicular stomatitis/measles virus (VSV/MV).
  • Assessment of viral replication kinetics and neurotoxicity.
  • Evaluation of in vivo anti-tumor activity in a myeloma xenograft model.
  • Comparison with parental viruses and a recombinant VSV (VSV-M51).

Main Results:

  • The hybrid VSV/MV demonstrated rapid replication similar to VSV.
  • The engineered virus lacked the neurotoxicity associated with VSV.
  • VSV/MV selectively targeted CD46 on tumor cells.
  • In vivo studies showed superior performance of VSV/MV compared to MV and VSV-M51 in reducing tumor burden.

Conclusions:

  • The hybrid VSV/MV is a promising oncolytic agent with improved safety and efficacy.
  • This novel virus architecture overcomes limitations of existing oncolytic viruses.
  • VSV/MV warrants further investigation as a potential cancer therapeutic.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.4K

Related Concept Videos

Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K